[vc_section el_class=”fond-gris”][vc_row max_width=”80″ wpex_bg_overlay=”custom” css=”.vc_custom_1632686442766{background-image: url(https://www.predilife.com/wp-content/uploads/2021/02/investisseurs.jpg?id=660) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” wpex_bg_position=”top left”][vc_column][vc_empty_space height=”120px”][vc_row_inner][vc_column_inner width=”1/2″][/vc_column_inner][vc_column_inner width=”1/2″][vc_column_text]

Predilife identity card and shares

[/vc_column_text][vc_empty_space height=”40px”][vc_column_text el_class=”stroke stroke-blanc”]Press Releases and Publications[/vc_column_text][vc_empty_space height=”180px”][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row css=”.vc_custom_1632145116081{background-color: #ffffff !important;}” el_class=”rangee-negative”][vc_column][vc_empty_space height=”40px”][vc_row_inner][vc_column_inner width=”1/4″][vc_single_image image=”3084″][vc_empty_space height=”40px”][/vc_column_inner][vc_column_inner width=”3/4″][vc_column_text]

Editorial

[/vc_column_text][vc_empty_space height=”30px”][vc_column_text]

« Since its creation, Predilife has been a company at the heart of predictive medicine, offering targeted and effective prevention through innovative devices based on artificial intelligence and Big Data. The company has succeeded in forging strategic agreements with the world’s largest breast cancer databases, enabling us to develop a predictive model for this pathology that is recognised in Europe.
MammoRisk®, the first solution developed by Predilife has now reached development maturity and is available in prestigious centres in France and Europe.
Predilife will now extend its offer to the main serious pathologies in order to remain a pioneering player in predictive medicine. »

Stéphane Ragusa,
Chairman and CEO of Predilife.

[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_empty_space height=”40px”][vc_row_inner][vc_column_inner width=”1/2″][vc_column_text el_class=”stroke-reverse”]

Predilife identity card

[/vc_column_text][vc_empty_space height=”30px”][vc_column_text]Listed on : Euronext Growth Paris
ISIN / Mnemo code : FR0010169920 / ALPRE
Date made public : 18 December 2018
Financial year end date : 31 décembre
Number of shares : 3 660 305
Finalisation of liquidity agreement : TSAF-Tradition Securities and Futures[/vc_column_text][vc_empty_space height=”20px”][vc_column_text font_weight=”700″]Shareholding of the company :[/vc_column_text][vc_column_text el_class=”bourse”]4,12 € au 24/04/2024 à 13:12[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″][vc_empty_space height=”30px” el_class=”marge-mobile”][vc_column_text el_class=”stroke-reverse”]

Shareholding of the company

[/vc_column_text][vc_empty_space height=”30px”][vc_round_chart type=”doughnut” style=”custom” stroke_width=”2″ values=”%5B%7B%22title%22%3A%22St%C3%A9phane%20RAGUSA%20%3A%2041.47%25%22%2C%22value%22%3A%2241.47%22%2C%22color%22%3A%22vista-blue%22%2C%22custom_color%22%3A%22%23192a56%22%7D%2C%7B%22title%22%3A%22Caravelle%20%3A%2022.09%25%22%2C%22value%22%3A%2222.09%22%2C%22color%22%3A%22pink%22%2C%22custom_color%22%3A%22%23475578%22%7D%2C%7B%22title%22%3A%22Antoine%20BRICARD%20%3A%2010.25%25%22%2C%22value%22%3A%2210.25%22%2C%22color%22%3A%22chino%22%2C%22custom_color%22%3A%22%23757f9a%22%7D%2C%7B%22title%22%3A%22Salari%C3%A9s%20%3A%201.04%25%22%2C%22value%22%3A%221.04%22%2C%22color%22%3A%22sky%22%2C%22custom_color%22%3A%22%23a3aabb%22%7D%2C%7B%22title%22%3A%22Divers%20%2F%20publics%20%3A%2025.15%25%22%2C%22value%22%3A%2225.15%22%2C%22color%22%3A%22pink%22%2C%22custom_color%22%3A%22%23d1d4dd%22%7D%5D”][/vc_column_inner][/vc_row_inner][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row el_class=”bouton-negatif”][vc_column][vc_column_text el_class=”nouveau-bouton” text_align=”center”]Access to press releases and publications[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space height=”60px”][/vc_column][/vc_row][/vc_section]